Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
MJFF Publications
Donate Now
Access Resources

MJFF Publications
4401 - 4410 of 9117 Results
Title
Year
  • Year
  • 2025
  • 2025
  • 2026
  • 2011
  • 2012
  • 2023
  • 2015
  • 2012
  • 2017
  • 2015
  • Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties
    2025
    Summary Details
    OPEN
    Title: Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties
    Author(s): Daniel Belete, Christian Mattjie, Brook Huxford, Jonathan P. Bestwick, Alastair J. Noyce, Cristina Simonet
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Vol: 13
    Issue #: 5
    Start Page: 1228
    End Page: 1235
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mdc3.70434
    Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.70434
    Citation Count: 0
  • A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults
    2025
    Summary Details
    OPEN
    Title: A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults
    Author(s): Jordan L. Schultz, Phillip E. Gander, Craig D. Workman, Laura L. Boles Ponto, Stephen Cross, Christopher Nance, Christopher L. Groth, Eric B. Taylor, Sarah E. Ernst, Jia Xu, Ergun Y Uc, Vincent A. Magnotta, Michael J. Welsh, Nandakumar S. Narayanan
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Vol: 15
    Issue #: 7
    Start Page: 1253
    End Page: 1263
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1177/1877718x251356503
    Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/1877718X251356503
    Citation Count: 2
  • The Age at Onset of LRRK2 p. Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin
    2026
    Summary Details
    OPEN
    Title: The Age at Onset of LRRK2 p. Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin
    Author(s): Theresa Lüth, Björn‐Hergen Laabs, Sebastian Sendel, Inke R. Koenig, Amke Caliebe, Alastair J Noyce, Laurel A. Screven, Soraya Bardien, Matthew Farrer, F. Hentati, Rim Amouri, Christine Klein, Samia Ben Sassi, Joanne Trinh, Global Parkinson's Genetics Program (GP2)
    Journal Name: Annals of Neurology
    Publisher: Wiley
    Vol: 99
    Issue #: 6
    Start Page: 1394
    End Page: 1404
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/ana.78181
    Best OA location URL: https://doi.org/10.1002/ana.78181
    Citation Count: 0
  • Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease
    2011
    Summary Details
    RESTRICTED
    Title: Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease
    Author(s): Samia Ben Sassi, Fatma Nabli, Emna Hentati, H. Nahdi, Meriam Trabelsi, Hela Ayed, Rim Amouri, John E. Duda, Matthew J. Farrer, Fayçal Hentati
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Vol: 18
    Issue #: 3
    Start Page: 243
    End Page: 246
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2011.10.009
    Citation Count: 48
  • Importance of the Brain Angiotensin System in Parkinson’s Disease
    2012
    Summary Details
    OPEN
    Title: Importance of the Brain Angiotensin System in Parkinson’s Disease
    Author(s): John W. Wright, Joseph W. Harding
    Journal Name: Parkinson's Disease
    Publisher: Wiley
    Vol: 2012
    Issue #:
    Start Page: 1
    End Page: 14
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1155/2012/860923
    Best OA location URL: https://downloads.hindawi.com/journals/pd/2012/860923.pdf
    Citation Count: 29
  • Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease
    2023
    Summary Details
    OPEN
    Title: Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease
    Author(s): Cornelis Blauwendraat, Nahid Tayebi, Elizabeth Geena Woo, Grisel Lopez, Luca Fierro, Marco Toffoli, Naomi Limbachiya, Derralynn Hughes, Vanessa Pitz, Dhairya Patel, Dan Vitale, Mathew J. Koretsky, Dena Hernández, Raquel Real, Roy N. Alcalay, Mike A. Nalls, Huw R. Morris, Anthony H.V. Schapira, Manisha Balwani, Ellen Sidransky
    Journal Name: Movement Disorders
    Publisher: Wiley
    Vol: 38
    Issue #: 5
    Start Page: 899
    End Page: 903
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.29342
    Best OA location URL: https://doi.org/10.1002/mds.29342
    Citation Count: 20
  • Targeting β-arrestin2 in the treatment ofl-DOPA–induced dyskinesia in Parkinson’s disease
    2015
    Summary Details
    OPEN
    Title: Targeting β-arrestin2 in the treatment ofl-DOPA–induced dyskinesia in Parkinson’s disease
    Author(s): Nikhil M. Urs, Simone Bido, Sean M. Peterson, Tanya L. Daigle, Caroline E. Bass, Raul R. Gainetdinov, Erwan Bézard, Marc G. Caron
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: National Academy of Sciences
    Vol: 112
    Issue #: 19
    Start Page: E2517
    End Page: 26
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1073/pnas.1502740112
    Best OA location URL: https://www.pnas.org/content/pnas/112/19/E2517.full.pdf
    Citation Count: 108
  • A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease
    2012
    Summary Details
    OPEN
    Title: A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease
    Author(s): Shankar J. Chinta, Subramanian Rajagopalan, Abirami Ganesan, Julie K. Andersen
    Journal Name: Parkinson's Disease
    Publisher: Wiley
    Vol: 2012
    Issue #:
    Start Page: 1
    End Page: 12
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1155/2012/364684
    Best OA location URL: https://downloads.hindawi.com/journals/pd/2012/364684.pdf
    Citation Count: 17
  • Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients
    2017
    Summary Details
    OPEN
    Title: Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients
    Author(s): Andrea M. Kälin, Min Tae M Park, M. Mallar Chakravarty, Jason P. Lerch, Lars Michels, Clemens Schroeder, Sarah D. Broicher, Spyros Kollias, Roger M. Nitsch, Anton Gietl, Paul G. Unschuld, Christoph Höck, Sandra E. Leh
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Vol: 9
    Issue #:
    Start Page: 38
    End Page: 38
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2017.00038
    Best OA location URL: https://doi.org/10.3389/fnagi.2017.00038
    Citation Count: 65
  • Thalamic deep brain stimulation for drug-induced tremor
    2015
    Summary Details
    RESTRICTED
    Title: Thalamic deep brain stimulation for drug-induced tremor
    Author(s): Bernardo Rodrigues, Parag G. Patil, Kelvin L. Chou
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Vol: 21
    Issue #: 11
    Start Page: 1369
    End Page: 1370
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2015.08.033
    Citation Count: 7
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.